@S34F mutation alters U2AF1 function, leading to aberrant alternative splicing of target genes.
>Okeyo-Owuor et al. Leukemia 2015; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391984/
$These data suggest that the S34F mutation alters U2AF1 function in the context of specific RNA sequences, leading to aberrant alternative splicing of target genes, some of which may be relevant for MDS pathogenesis.

@CUX1 deficiency activates PI3K signaling, leading to increased tumor growth and susceptibility to PI3K-AKT inhibition.
>Wong et al. Nature Genetics 2014; http://www.nature.com/ng/journal/v46/n1/abs/ng.2846.html
$We demonstrate that CUX1 deficiency activates phosphoinositide 3-kinase (PI3K) signaling through direct transcriptional downregulation of the PI3K inhibitor PIK3IP1 (phosphoinositide-3-kinase interacting protein 1), leading to increased tumor growth and susceptibility to PI3K-AKT inhibition.

@Mutations in ATM, RB1, and FANCC predict response to cisplatin-based chemotherapy in Muscle-invasive Bladder Cancer.
>Plimack et al. European Urology 2015; https://www.ncbi.nlm.nih.gov/pubmed/26238431
$Genomic alterations in the DNA repair-associated genes ATM, RB1, and FANCC predict response and clinical benefit after cisplatin-based chemotherapy for MIBC

@Loss of ADAMTS15 expression predicts poor prognosis in breast cancer.
>Porter et al. Int J Cancer 2006; https://www.ncbi.nlm.nih.gov/pubmed/16152618
$For both RFS and OS, the group with high ADAMTS8 and low ADAMTS15 expression had a particularly poor prognosis.

@ADAMTS15 expression inhibits breast cancer cell migration.
>Wagstaff et al. Breast Cancer Res. 2010; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875577/
$ADAMTS15 metalloproteinase inhibits breast cancer cell migration.

@ADAMTS15 restrains tumor growth and invasion in mouse models of colorectal cancer.
>Viloria et al. Cancer Res. 2009; http://cancerres.aacrjournals.org/content/69/11/4926
$Moreover, functional in vitro and in vivo studies using HCT-116 and SW-620 colorectal cancer cells and severe combined immunodeficient mice have revealed that ADAMTS15 restrains tumor growth and invasion.

@JAK2 p.V617F mutation largely absent from pancreatic cancer (28 patients, 10 cell lines).
>Kocher et al. Gut, 2007; http://gut.bmj.com/content/56/8/1174.short
$JAK V617F missense mutation is absent in pancreatic cancer.

@GNAS mutation present in 66% of IPMNs.
>Furukawa et al. Scientific Reports 2011; https://www.nature.com/articles/srep00161
$They found that 66% of 132 IPMNs harbored a GNAS mutation, 81% harbored a KRAS mutation, and slightly more than half (51%) harbored both GNAS and KRAS mutations, whereas at least 1 of the 2 genes was mutated in 96.2%.

@Constitutive activation of Gsalpha and adenylate cyclase and to lead to the autonomous synthesis of cyclic adenosine monophosphate (cAMP).
>Wilson et al. Oncogene 2010; http://www.nature.com/onc/journal/v29/n32/full/onc2010202a.html
$The GNAS R201C mutation has been shown to result in the constitutive activation of Gsα and adenylate cyclase and to lead to the autonomous synthesis of cyclic adenosine monophosphate (cAMP).

@GNAS R201C mutation activates Wnt and ERK1/2, MAPK pathways.
>Wilson et al. Oncogene 2010; http://www.nature.com/onc/journal/v29/n32/full/onc2010202a.html
$The activating mutation R201C in GNAS promotes intestinal tumourigenesis in ApcMin/+ mice through activation of Wnt and ERK1/2 MAPK pathways.

@GNAS R201C mutation causes elevated Wnt and ERK, MAPK phosphorylation.
>Wilson et al. Oncogene 2010; http://www.nature.com/onc/journal/v29/n32/full/onc2010202a.html
$Gpa33tm1(GnasR201C)Wtsi/+ mice showed significantly elevated cAMP levels and a compensatory upregulation of cAMP-specific phosphodiesterases in the intestinal epithelium.

@MYOM3 -- Myomesin 3 may link the intermediate filament cytoskeleton to the M-disk of the myofibrils in striated muscle.
>GeneCards; http://www.genecards.org/cgi-bin/carddisp.pl?gene=MYOM3
$May link the intermediate filament cytoskeleton to the M-disk of the myofibrils in striated muscle.

@PPP2R2A -- Protein phosphatase 2A (PP2A) is a major cellular phosphatase and plays key regulatory roles in growth, differentiation, and apoptosis.
>Dupont et al. Cancer 2010; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807897/
$Protein phosphatase 2A (PP2A) is a major cellular phosphatase and plays key regulatory roles in growth, differentiation, and apoptosis

@PPP2R2A is a tumor suppressor gene in breast cancer
>Dupont et al. Cancer 2010; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807897/
$This evidence supports the previously hypothesized role of PP2A as a tumor suppressor gene in breast cancer.

@CDK4/6 inhibition has some efficacy in primary pancreatic cancer PDX
>Witkiewicz et al. Oncotarget 2015; http://pubmedcentralcanada.ca/pmcc/articles/PMC4599237/
$Together, these data indicate that primary PDA is sensitive to CDK4/6 inhibition, that specific biomarkers can delineate intrinsic resistance, and that established cell line models may not represent an adequate means for evaluating therapeutic sensitivities.

@Pancreatic cancers are TRAIL therapy resistant.
>Chen et al. Cancer Lett. 2014; https://experts.umn.edu/en/publications/
$The tumor necrosis factor related apoptosis-inducing ligand (TRAIL) causes cancer cell death, but many cancers, including pancreatic cancer, are resistant to TRAIL therapy.

@Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway by increasing levels of TNFRSF10B.
>Chen et al. Cancer Lett. 2014; https://experts.umn.edu/en/publications/triptolide-sensitizes-pancreatic-cancer-cells-to-trail-induced-ac
$Triptolide induced increase in DR5 expression sensitizes pancreatic cancer cells to TRAIL mediated cell death.

@GLI3 is mutated in 6% of PDA.
> Witkiewicz et al. Nat. Comm. 2015; https://www.nature.com/articles/ncomms7744
$We also identified a number of ‘cancer genes’18 as significantly mutated in PDA, including BCLAF1 (5% of cases), IRF6 (4% of cases), FLG (10% of cases), AXIN1 (5% of cases), GLI3 (6% of cases) and PIK3CA (4% of cases).

@Gli3 mediates cell survival and sensitivity to cyclopamine in pancreatic cancer.
>Steg et al. Cancer Biol Ther 2010; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230294/
$Gli3 mediates cell survival and sensitivity to cyclopamine in pancreatic cancer.

@MLK4 is a negative regulator of TLR4 signaling.
>Seit-Nebi et al. Cell Mol. Immunol. 2012; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161176/
$MLK4 has a negative effect on TLR4 signaling.

@MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis.
>Martini et al. Cancer Res. 2013; http://cancerres.aacrjournals.org/content/canres/early/2013/01/12/0008-5472.CAN-12-3074.full.pdf
$We also reported that MLK4 mutant alleles are unable per se to promote
transformation, but synergistically cooperate with activated RAS to drive
tumorigenesis.

@TET2 is a tumor suppressor in 7-13% of myeloproliferative neoplasms, 19-26% of myelodysplastic syndromes.
>Patriarca et al. BioMed Res. Intern. 2013; https://www.hindawi.com/journals/bmri/2013/929840/
$In particular, alterations in the TET2 gene, a putative tumor suppressor gene located at chromosomal region 4q24, have been identified in 7–13% of MPN patients, in 19–26% myelodysplastic syndromes (MDSs), in 12–24% of acute myeloid leukemia (AML), in 20–40% of chronic myelomonocytic leukemia (CMML), and in 29% of systemic mastocytosis [2–9].

@TSC2 complexes with TSC1 and inhibits the nutrient-mediated or growth factor-stimulated phosphorylation of S6K1 and ElF4EBP1 by negatively regulating mTORC1 signaling.
>Dey et al. Humana Press 2016; https://books.google.com/books?id=pAxkDAAAQBAJ&printsec=frontcover#v=onepage&q&f=false
$In complex with TSC2, TSC1 protein inhibits nutrient-mediated or growth factor-stimulated phosphorylation of S6K1 and EIF4EBP1 by negatively regulating mTORC1 signaling.

@Loss of function of the TSC2 tumor suppressor is a driver event in lymphangioleiomyomatosis.
>Giannikou et al. PLOS Gen. 2016; http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006242
$Our results indicate that TSC2 and less commonly TSC1 alterations are the primary essential driver event in angiomyolipoma/LAM, whereas other somatic mutations are rare and likely do not contribute to tumor development.

@U2AF1 encodes the small subunit which plays a critical role in both constitutive and enhancer-dependent RNA splicing.
>NCBI Gene 2017; https://www.ncbi.nlm.nih.gov/gene/7307
$This gene encodes the small subunit which plays a critical role in both constitutive and enhancer-dependent RNA splicing by directly mediating interactions between the large subunit and proteins bound to the enhancers

@U2AF1 mutation is identified in many cancer types, myelodysplastic syndromes.
>Graubert et al. Nat. Gen. 2012; http://www.nature.com/ng/journal/v44/n1/full/ng.1031.html
$Here we show that a missense mutation affecting the serine at codon 34 (Ser34) in U2AF1 was recurrently present in 13 out of 150 (8.7%) subjects with de novo MDS, and we found suggestive evidence of an increased risk of progression to sAML associated with this mutation.

@GLI3 is a transcriptional activator and repressor of hedgehog signaling target genes.
>Pan et al. Mol. Cell Biol. 2006; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1447407/
$Gli3 mainly acts as a transcriptional repressor, because the majority of full-length Gli3 protein is proteolytically processed. 

@CSMD3 is the 2nd most common mutation in lung cancers (22%), common in other types.
>Pengyuan et al. Carcinogen. 2012; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499051/
$Notably, a novel gene CSMD3 was identified as the second most frequently mutated gene (next to TP53) in lung cancer.

@CDK6 amplification promotes G1/S transition of the cell cycle by phosphorylating RB
>Yang et al. Oncogene 2017; http://www.nature.com/onc/journal/v36/n16/full/onc2016379a.html
$Amplification of CDK6 resulted in a marked increase in CDK6 expression and reduced response of the CDK4/6 target, phospho-Rb (pRb), to CDK4/6 inhibitors

@Mutation of JAK2 causes constitutive activation and signaling through STAT3.
>Looyenga et al. PLOS One 2012; http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0030820
$An essential role for JAK2/STAT3 has been most clearly identified in myeloproliferative disorders (polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis) and several different myeloid malignancies (atypical CML, CMML, megakaryocytic AML, JMML), all of which bear a high proportion of somatic JAK2 mutations (i.e. V617F) that lead to constitutive kinase activation

@ PPP2R2A loss of function is implicated in DSB repair.
>Kalev et al. Cancer Res. 2012; http://cancerres.aacrjournals.org/content/72/24/6414.long
$Here, we report the results of a loss-of-function screen that identifies the PP2A heterotrimeric serine/threonine phosphatases PPP2R2A, PPP2R2D, PPP2R5A, and PPP2R3C in double-strand break (DSB) repair.